Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note

Rhea-AI Summary

Outlook Therapeutics (OTLK) has announced the full cash pre-payment of its unsecured convertible promissory note, dated November 4, 2020, to strengthen its financial position ahead of a potential FDA approval for ONS-5010 (bevacizumab-vikg). The repayment, which eliminates the risk of dilution from converting the note into common stock at a discount, allows the company to maintain investor confidence. The note, which had a face amount of $10,220,000, was initially amended to extend its maturity and increase interest rates, reflecting the company’s focus on upcoming regulatory hurdles.

Positive

• Elimination of potential dilution for shareholders by repaying the convertible promissory note.
• Strengthened financial position supports potential FDA approval and launch of ONS-5010.

Negative

• The interest rate on the note was increased from 7.5% to 10%, indicating higher financial costs.

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today the full cash pre-payment of its unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021 (the “Note”). All obligations under the Note have been repaid in cash and satisfied.

“The company requires a good financial position to support the potential FDA approval and subsequent launch of ONS-5010/ LYTENAVA™ (bevacizumab-vikg),” commented Lawrence A. Kenyon, Chief Financial Officer of Outlook Therapeutics. “We are also mindful of current financial market conditions and the potential for dilution to our stockholders. We are pleased to be in a position to fully repay this unsecured convertible promissory note to prevent the dilution associated with redemption of the Note for common stock at a 25% discount to market price that could have begun on July 1, 2022.”

On November 5, 2020, the Company received $10,000,000 in net proceeds from the Note with face amount of $10,220,000, which was amended in November 2021 and became convertible. On November 16, 2021, the Company entered into a note amendment which, among other things, (i) extended the maturity date to January 1, 2023, (ii) increased the interest rate from 7.5% per annum to 10% per annum beginning on January 1, 2022, and (iii) provided for the lender’s right to redeem some or all of the outstanding balance of the note for shares of the Company’s common stock beginning July 1, 2022, subject to certain limitations.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a pre-commercial biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. For more information, please visit www.outlooktherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “will,” the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. These include, among others, statements about ONS-5010’s potential as the first FDA-approved ophthalmic formulation of bevacizumab-vikg and commercial launch of ONS-5010. Although Outlook Therapeutics believes that it has a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting Outlook Therapeutics and are subject to risks, uncertainties and factors relating to its operations and business environment, all of which are difficult to predict and many of which are beyond its control. These risk factors include those risks associated with developing pharmaceutical product candidates, risks of conducting clinical trials and risks in obtaining necessary regulatory approvals, as well as those risks detailed in Outlook Therapeutics’ filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the fiscal year ended September 30, 2021 and subsequent Quarterly Reports on Form 10-Q, which include the uncertainty of future impacts related to the ongoing COVID-19 pandemic. These risks may cause actual results to differ materially from those expressed or implied by forward-looking statements in this press release. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Outlook Therapeutics does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

CONTACTS:

Media Inquiries:
Harriet Ullman
Vice President
LaVoie Health Science
T: 617-669-3082
hullman@lavoiehealthscience.com

Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com

FAQ

What is the significance of Outlook Therapeutics' recent note repayment?

The repayment eliminates dilution risks for shareholders and strengthens the company's financial position as it seeks FDA approval for ONS-5010.

How does the note repayment impact OTLK stock?

By avoiding dilution through conversion, the repayment is likely to maintain or improve shareholder confidence in OTLK.

What are the terms of the unsecured convertible promissory note repaid by Outlook Therapeutics?

The note had a face amount of $10,220,000, with an interest rate that was increased to 10% after the amendment.

When did Outlook Therapeutics repay its convertible promissory note?

The full cash pre-payment was announced on July 5, 2022.

What does the repayment of the note mean for the future of ONS-5010?

The repayment allows Outlook Therapeutics to pursue FDA approval for ONS-5010 without the risk of stockholder dilution.